Novo Nordisk lowers sales outlook, lawsuit filed against company.

• Novo Nordisk A/S faces class action lawsuit for securities fraud allegations. • Lawsuit filed by Pomerantz LLP against the company and certain officers/directors. • Investors who purchased Novo Nordisk securities during the Class Period can seek lead plaintiff appointment. • Complaint available at www.pomerantzlaw.com. • Deadline to apply for lead plaintiff is September 30, 2025. • Contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980 for more information.

Novo Nordisk A/S (NVO) is the subject of a class action lawsuit alleging securities fraud, filed by Pomerantz LLP. The lawsuit claims that the company and its officers/directors made false and misleading statements to investors regarding the company's growth potential and the impact of the personalization exception to the compounded GLP-1 exclusion. Investors who purchased Novo Nordisk securities during the Class Period, which runs from May 7, 2025, to July 28, 2025, can seek lead plaintiff appointment by contacting Danielle Peyton at newaction@pomlaw.com or 646-581-9980.

The complaint, available at www.pomerantzlaw.com, alleges that Novo Nordisk overstated its ability to capitalize on the compounded market and understated the impact of the personalization exception to the compounded GLP-1 exclusion. The company's stock price fell significantly on July 29, 2025, following the announcement of lower sales outlook for 2025, highlighting the potential impact of the lawsuit on the company's financial performance.

Investors should carefully consider the potential implications of the class action lawsuit and the recent guidance adjustments on Novo Nordisk's stock price and financial performance. The company's ability to navigate these challenges will be crucial for its future growth prospects.

References:
[1] https://www.businesswire.com/news/home/20250803095181/en/NVO-Investors-Have-Opportunity-to-Lead-Novo-Nordisk-AS-Securities-Fraud-Lawsuit-with-the-Schall-Law-Firm
[2] https://www.ainvest.com/news/novo-nordisk-investors-file-securities-fraud-class-action-lawsuit-2508/
[3] https://www.morningstar.com/news/pr-newswire/20250806dc46076/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-novo-nordisk-as-of-class-action-lawsuit-and-upcoming-deadlines-nvo
[4] https://www.morningstar.com/news/pr-newswire/20250803ny42967/faruqi-faruqi-reminds-novo-nordisk-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-september-30-2025-nvo